Santini V, Komrokji RS, Savona MR, Díez-Campelo M, Fenaux P, Sekeres MA, Madanat YF, Valcárcel D, Jonášová A, Belohlavkova P, Berry T, Dougherty S, Shah S, Xia Q, Sun L, Wan Y, Huang F, Feller F, Navada S, Zeidan AM, Platzbecker U. Overall survival and long-term outcomes from the randomized, double-blind, placebo-controlled, phase III IMerge trial of imetelstat for lower-risk myelodysplastic syndromes. haematol [Internet]. 2020Sep.10 [cited 2026Sep.16];. Available from: https://haematologica.org/article/view/14398